A Japanese review team from Keio University, the University of Tokyo, and Fujita Health University surveyed a decade of systematic reviews and meta-analyses on preventing sarcopenia, the age-related loss of muscle mass, strength, and physical function that affects an estimated 10 to 16 percent of older adults worldwide. Their conclusion is blunt: no pharmacological treatment has been established, and resistance training remains the only intervention with consistent, moderate-to-large effects across muscle mass, strength, and physical performance. Nutritional supplementation (leucine, HMB, vitamin D, omega-3) produces small and inconsistent effects when used alone, and its apparent benefits often disappear once resistance training is present in the comparison. Electrical muscle stimulation shows promise as a substitute for people who cannot exercise, but the evidence base is small and graded low quality. The review’s most forward-looking section argues that chronic low-grade inflammation, driven in part by periodontitis and gut dysbiosis, is an underappreciated upstream driver of muscle loss and a plausible therapeutic target.
The pharmaceutical industry has spent two decades chasing a drug for age-related muscle loss. This review, published in Osteoporosis and Sarcopenia, opens by conceding that the search has failed. Nothing is approved. Nothing is established. What remains is what worked in 1975: progressive resistance training, performed two to three times per week.
The big idea here is not the training recommendation itself, which is unsurprising. It is the hierarchy the authors construct by stacking the meta-analyses side by side. When you line up the pooled effect sizes, resistance training produces moderate to large gains in lower limb strength and functional performance, while nutritional supplementation alone produces effects that hover near the threshold of detectability. More pointedly, when one meta-analysis of whey protein plus vitamin D separated participants who were also lifting weights from those who were not, the supplement effects vanished in the lifting group. The supplements were not adding to the training. The training was doing the work, and the supplements were filling a gap that only existed when the training was absent.
The second idea is more speculative and more interesting. The authors devote roughly a third of the paper to chronic inflammation, and specifically to the mouth. Periodontitis, a bacterial inflammatory disease of the gums affecting a large fraction of older adults, elevates circulating IL-6, TNF-alpha, and C-reactive protein. Those cytokines activate NF-kB signaling in skeletal muscle, which drives proteolysis and suppresses protein synthesis. In a rodent model, experimentally induced periodontitis worsened muscle atrophy caused by immobilization. In another, infection with the periodontal pathogen Porphyromonas gingivalis altered the gut microbiome and impaired glucose uptake in skeletal muscle, suggesting the mouth influences muscle through a metabolic detour rather than by direct cytokine assault.
The human epidemiology is thinner. In a cross-sectional analysis of US adults, periodontitis severity tracked with weaker grip strength but showed no correlation with muscle mass at all. Oral health appears to degrade muscle function before, or instead of, muscle mass. Whether treating gum disease preserves muscle has not been tested, and the authors say so plainly.
A third strand concerns people who cannot train at all. Electrical muscle stimulation activates much of the same machinery as voluntary exercise and reported gains of 10 to 15 percent in muscle mass and function over five to six weeks. But the evidence was graded low quality, and whole-body devices carry a rhabdomyolysis risk serious enough that Germany regulates them. A bridge for the immobilized, not a shortcut for the unmotivated.
Actionable Insights
Effect size, not the p-value, is the number to watch. A p-value says an effect probably is not zero. An effect size says how big it is. Cohen’s d of 0.2 is small, 0.5 moderate, 0.8 large. At d of 0.8, if you pick one trained and one untrained person at random, the trained one wins about 71 percent of the time. At d of 0.2 it is 56 percent, barely better than a coin flip.
Resistance training, two to three sessions weekly for roughly 23 weeks, produced 0.93 for lower limb strength (large), 0.76 for functional performance, 0.75 for gait speed, 0.51 for grip strength, and 0.29 for muscle mass (small). You get strong and functional well before you get bigger, and if the goal is staying out of a care home, that ordering favors you.
Supplements underperform badly. HMB moved fat-free mass by 0.35 with no strength effect. Leucine alone added roughly 1 kg of lean mass, again with no strength benefit. Protein supplementation raised muscle protein synthesis by 1.08 while moving lean body mass by only 0.18, which was not statistically significant. Anabolic signaling is not the same thing as muscle you can use.
Train first, treat gum disease, and treat supplements as insurance against low protein intake rather than as an intervention.
Context and Source
- Open Access Paper: Sarcopenia prevention in older adults: Effectiveness and limitations of non-pharmacological interventions
- Authors: Doyoon Kim, Satoru Morikawa, Masashi Miyawaki, Taneaki Nakagawa, Sumito Ogawa, Yoshitaka Kase
- Institutions: Keio University School of Medicine (Tokyo); Graduate School of Medicine, The University of Tokyo; Regenerative Medicine Research Center, Keio University (Kawasaki); International Center for Brain Science, Fujita Health University (Aichi)
- Country: Japan
- Journal: Osteoporosis and Sarcopenia
- Article type: Narrative review, part of a special issue on sarcopenia.
- Impact evaluation: The impact score of this journal is 2.4 (Journal Impact Factor; 5-year JIF 2.8), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.